Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Other Non-current Assets

Long-term assets not reported separately.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Other non-current assets rises 7.6% from a year ago

Other non-current assets stood at $10.82M at the end of Q1 FY2026, up 7.6% from a year earlier and down 2.3% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.

Context

  • Other non-current assets amounted to 2.5% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
  • Other non-current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether other non-current assets keeps rising in the next quarterly balance sheet after a +7.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.82M-2.3% QoQ
Last fiscal yearDec 2025
$11.08M+21.8% YoY
Year agoMar 2025
$10.06M+7.6% since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year+21.8%——
3-year CAGR-0.9%——
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
11.08M USD
Year-over-year change
+21.8%
4-year CAGR
+8.0%

Other Non-current Assets vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's Mar 2026 other non-current assets of $10.82M is the 3rd highest of the 11 companies compared; the peer median is $2.54M.
  • Its year-over-year change of +7.6% is the 4th highest of 11, against a peer median of -59.8%.
  • Other non-current assets amounts to 2.5% of total assets for VNDA, versus a peer median of 0.9%.
VNDA Competitors Peer median
Other Non-current Assets for VNDA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$42.19B +5202413.6%+291.0%19.6%
VYGRVoyager Therapeutics, Inc.Mar 2026$32.92M +1045.3%+74.0%15.0%
VNDAVanda Pharmaceuticals Inc.Mar 2026$10.82M +7.6%-0.9%2.5%
ALLOAllogene Therapeutics, Inc.Mar 2026$3.53M -89.6%+23.5%0.9%
TRDAEntrada Therapeutics, Inc.Mar 2026$3.38M -19.3%-28.4%1.0%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$3.05M -30.6%+28.0%1.1%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$2.03M -89.0%—0.8%
CAPRCapricor Therapeutics, Inc.Mar 2026$1.53M +505.3%+279.8%0.5%
HUMAHumacyte, Inc.Mar 2026$672K -98.7%—0.6%
ACHVAchieve Life Sciences, Inc.Mar 2026$30K -90.0%—0.1%
SGMTSagimet Biosciences Inc.Mar 2026$0 -100.0%—0.0%
Peer median (excluding VNDA) $2.54M-59.8%+51.0%0.9%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents52.07M135.03M135.82M102.32M84.85M
Short-term Investments380.74M331.83M252.44M272.33M179M
Net Receivables32.47M33.51M34.16M47.1M54.58M
Inventory1.02M1.19M1.36M1.73M1.85M
Other Current Assets117.73M9.17M15.42M26.99M
Total Current Assets478.3M519.29M432.95M438.89M347.26M
Property, Plant & Equipment (Net)12.39M10.97M9.14M12.68M13.51M
Goodwill00000
Intangible Assets20.08M18.57M121.37M114.1M117.09M
Long-term Investments00000
Tax Assets74.88M74.04M75M81.44M0
Other Non-current Assets8.15M11.38M9.99M9.1M11.08M
Total Non-current Assets115.49M114.96M215.49M217.31M141.69M
Total Assets593.79M634.25M648.44M656.2M488.95M
Account Payables925K12.69M7.15M3.5M4.94M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities27.68M34.01M69.33M69.36M87.19M
Total Current Liabilities74.42M91.44M87.7M99.98M145.16M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities4.39M6.8M8.83M9.59M9.53M
Total Non-current Liabilities14.45M15.61M15.83M17.68M16.6M
Total Liabilities88.86M107.05M103.53M117.66M161.76M
Common Stock56K57K58K58K59K
Retained Earnings(164.18M)(157.9M)(155.39M)(174.29M)(394.77M)
Accumulated OCI(175K)(1.19M)(30K)74K629K
Other Stockholders Equity00000
Minority Interest00000
Total Equity504.93M527.2M544.91M538.55M327.19M
Total Debt12.37M11.14M9.4M12.36M12.62M
Net Debt(39.71M)(123.89M)(126.42M)(89.96M)(72.23M)

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.